Yes, stoppage for Overwhelming Benefit is extremel
Post# of 148256
(Total Views: 537)
Posted On: 10/20/2020 10:41:04 AM
Re: generactor #62171
Yes, stoppage for Overwhelming Benefit is extremely rare and continuing the trial was the most likely recommendation.
But COVID S/C approval is arguably the closest CYDY has ever been to the "brass ring". Once they get approved for anything COIVD, all other indications will eventually fall into place (CYDY mgmt obviously knows this).
As others have stated, the key question for NP is why didn't CYDY keep their foot on the gas pedal for CD-12 enrollment since late August, given that CD-12 trail continuation was the most likely outcome?
Is CYDY too small to focus on many things at once? Was it too expense to push enrollment without hearing the DSMC recommendation?
IMO, for the second half of this year, finishing CD-12 has been and continues to be vastly more important than M/M, NASH, GVHD, Cancer, Long Hauler, BBB, etc. research.
Everything else in 2020 is just a distraction at this point.
But COVID S/C approval is arguably the closest CYDY has ever been to the "brass ring". Once they get approved for anything COIVD, all other indications will eventually fall into place (CYDY mgmt obviously knows this).
As others have stated, the key question for NP is why didn't CYDY keep their foot on the gas pedal for CD-12 enrollment since late August, given that CD-12 trail continuation was the most likely outcome?
Is CYDY too small to focus on many things at once? Was it too expense to push enrollment without hearing the DSMC recommendation?
IMO, for the second half of this year, finishing CD-12 has been and continues to be vastly more important than M/M, NASH, GVHD, Cancer, Long Hauler, BBB, etc. research.
Everything else in 2020 is just a distraction at this point.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼